Literature DB >> 35377944

Heart Failure, Precision Medicine, and Incremental Equity: The Case of Hereditary Amyloid Cardiomyopathy.

Melvin R Echols1, Herman Taylor1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35377944      PMCID： PMC9047001          DOI： 10.1001/jama.2022.2360

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   157.335


× No keyword cloud information.
  11 in total

Review 1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Card Fail       Date:  2017-04-28       Impact factor: 5.712

2.  Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.

Authors:  Vibhu Parcha; Gargya Malla; Marguerite R Irvin; Nicole D Armstrong; Suzanne E Judd; Leslie A Lange; Mathew S Maurer; Emily B Levitan; Parag Goyal; Garima Arora; Pankaj Arora
Journal:  JAMA       Date:  2022-04-12       Impact factor: 157.335

3.  Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.

Authors:  Scott M Damrauer; Kumardeep Chaudhary; Judy H Cho; Lusha W Liang; Edgar Argulian; Lili Chan; Amanda Dobbyn; Marie A Guerraty; Renae Judy; Jenna Kay; Rachel L Kember; Michael G Levin; Aparna Saha; Tielman Van Vleck; Shefali S Verma; JoEllen Weaver; Noura S Abul-Husn; Aris Baras; Julio A Chirinos; Brian Drachman; Eimear E Kenny; Ruth J F Loos; Jagat Narula; John Overton; Jeffrey Reid; Marylyn Ritchie; Giorgio Sirugo; Girish Nadkarni; Daniel J Rader; Ron Do
Journal:  JAMA       Date:  2019-12-10       Impact factor: 56.272

4.  Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients.

Authors:  Aditi Nayak; Albert J Hicks; Alanna A Morris
Journal:  Circ Heart Fail       Date:  2020-08-13       Impact factor: 8.790

5.  Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

Authors:  Mazen Hanna; Thibaud Damy; Martha Grogan; Michelle Stewart; Balarama Gundapaneni; Terrell A Patterson; Jeffrey H Schwartz; Marla B Sultan; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2020-11-19       Impact factor: 2.778

6.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).

Authors:  David T Miller; Kristy Lee; Adam S Gordon; Laura M Amendola; Kathy Adelman; Sherri J Bale; Wendy K Chung; Michael H Gollob; Steven M Harrison; Gail E Herman; Ray E Hershberger; Teri E Klein; Kent McKelvey; C Sue Richards; Christopher N Vlangos; Douglas R Stewart; Michael S Watson; Christa Lese Martin
Journal:  Genet Med       Date:  2021-05-20       Impact factor: 8.822

7.  Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Arjun Sinha; Yinan Zheng; Drew Nannini; Yishu Qu; Lifang Hou; Sanjiv J Shah; Clyde W Yancy; Elizabeth M McNally; Myriam Fornage; Joao Lima; Donald M Lloyd-Jones; Laura J Rasmussen-Torvik; Sadiya S Khan
Journal:  JAMA Cardiol       Date:  2020-12-23       Impact factor: 14.676

8.  Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.

Authors:  Amanda C Coniglio; Matthew W Segar; Rahul S Loungani; Jainy J Savla; Justin L Grodin; Ervin R Fox; Sonia Garg; James A de Lemos; Jarett D Berry; Mark H Drazner; Sanjiv Shah; Michael E Hall; Amil Shah; Sadiya S Khan; Robert J Mentz; Ambarish Pandey
Journal:  JACC Heart Fail       Date:  2021-12-08       Impact factor: 12.544

9.  Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.

Authors:  Thibaud Damy; Pablo Garcia-Pavia; Mazen Hanna; Daniel P Judge; Giampaolo Merlini; Balarama Gundapaneni; Terrell A Patterson; Steven Riley; Jeffrey H Schwartz; Marla B Sultan; Ronald Witteles
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

10.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.